D’Andrea, David
Black, Peter C.
Zargar, Homayoun
Zargar-Shoshtari, Kamran
Soria, Francesco
Fairey, Adrian S.
Mertens, Laura S.
Dinney, Colin P.
Mir, Maria C.
Krabbe, Laura-Maria
Cookson, Michael S.
Jacobsen, Niels-Erik
Montgomery, Jeffrey S.
Vasdev, Nikhil
Yu, Evan Y.
Xylinas, Evanguelos
Campain, Nicholas J.
Kassouf, Wassim
Dall’Era, Marc A.
Seah, Jo-An
Ercole, Cesar E.
Horenblas, Simon
Sridhar, Srikala S.
McGrath, John S.
Aning, Jonathan
Wright, Jonathan L.
Thorpe, Andrew C.
Morgan, Todd M.
Holzbeierlein, Jeff M.
Bivalacqua, Trinity J.
North, Scott
Barocas, Daniel A.
Lotan, Yair
Grivas, Petros
Stephenson, Andrew J.
Shah, Jay B.
van Rhijn, Bas W.
Daneshmand, Siamak
Spiess, Philippe E.
Shariat, Shahrokh F. http://orcid.org/0000-0002-6627-6179
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 29 April 2021
Accepted: 19 July 2021
First Online: 9 August 2021
Declarations
:
: Dr. D'Andrea has nothing to disclose. Dr. Black reports personal fees from AbbVie, Asieris, Astra-Zeneca, Astellas, Bayer, Biosyent, BMS, EMD-Serono, H3-Biomedicine, Janssen, Merck, Roche, Sanofi, Urogen, Ferring, TerSera, Pfizer, Decipher Biosciences, iProgen, Genentech, MDx Health outside the submitted work; In addition, Dr. Black shares a patent with Decipher Biosciences. Dr. Zargar has nothing to disclose. Dr. Zargar-Shoshtari has nothing to disclose. Dr. Soria has nothing to disclose. Dr Fairey has nothing to disclose. Dr. Mertens has nothing to disclose. Dr. Dinney has nothing to disclose. Dr Mir has nothing to disclose. Dr. Krabbe has nothing to disclose. Dr. Cookson reports personal fees from Myovant Sciences, Jannsen, Astellas, Bayer, Ferring outside of the submitted work. Dr. Jacobsen has nothing to disclose. Dr Montgomery has nothing to disclose. Dr. Vasdev has nothing to disclose. Dr. Yu reports personal fees from Amgen, personal fees from Astra-zeneca, grants and personal fees from Bayer, personal fees from Clovis, grants and personal fees from Dendreon, personal fees from Janssen, grants and personal fees from Merck, personal fees from Pharmacyclics, grants and personal fees from Seagen, outside the submitted work. Dr. Xylinas has nothing to disclose. Dr. Campain has nothing to disclose. Dr. Kassouf reports personal fees from Janssen, Ferring, Sesen bio, Merck, Roche, Astellas outside of the submitted work. Dr. Dall'Era has nothing to disclose. Dr. Seah has nothing to disclose. Dr. Ercole has nothing to disclose. Dr. Horenblas has nothing to disclose. Dr. Sridhar reports personal fees from Pfizer, Merck, Roche, BMS, Bayer, Astra-Zeneca, Astellas, Janssen, Immunomedex, grant from Bayer, Janssen, Pfizer outside of the submitted work. Dr. McGrath has nothing to disclose. Dr. Aning has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Thorpe has nothing to disclose. Dr Morgan has nothing to disclose. Dr Holzbeierlein reports advisory board for Basilea outside of the submitted work. Dr. Bivalacqua has nothing to disclose. Dr. North has nothing to disclose. Dr. Barocas has nothing to disclose. Dr. Lotan reports advisory board or personal fees for C2I genomics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Cleveland Diagnostics, BMS, Nucleix, Abbott, Cepheid, Pacific Edge. FKD, MDxHealth, Biocancell, GenomeDx Biosciences, Storz, Vessi Medical, CAPs Medical outside of the submitted work. Dr. Grivas reports personal fees from Astra-Zeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dyania Health, Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; Genzyme; GlaxoSmithKline; Heron Therapeutics; Immunomedics, Janssen; Merck; Mirati Therapeutics; Pfizer; Seagen; QED Therapeutics. Research Funding to Institution from Merck; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb, QED Therapeutics, GlaxoSmithKline, Kure It Cancer Research outside of the submitted work. Dr. Stephenson has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Rhijn has nothing to disclose. Dr. Daneshmand reports personal fees from Janssen, Ferring, Photocure, Taris, Spectrum, Pacific Edge, QED, Abbvie, Johnson & Johnson, Seagen, Nucleix, Aduro, BMS outside of the submitted work. Dr. Spiess has nothing to disclose. Dr. Shariat reports personal fees from Astellas, Astra-Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, Wolff, outside the submitted work; in addition he has following patents Method to determine prognosis after therapy for prostate cancer; Granted 2002-09-06, Method to determine prognosis after therapy for bladder cancer; Granted 2003-06-19, Prognostic methods for patients with prostatic disease; Granted 2004-08-05, Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma; Granted 2010-07-20.
: All authors give their consent to publish the article in the current form.
: Not applicable.
: Not applicable for retrospective deidentified data.